Background: Large-scale genome-wide association studies (GWAS) have implicated many
Introduction
Antipsychotics target synaptic signaling by changing neurotransmission of the dopamine D2 receptor (DRD2) and the serotonin 5-HT 2 receptor (1, 2) . These drugs are the mainstay treatment modality in schizophrenia and are fairly effective at reducing positive symptoms (3) . However, improving the cognitive and negative symptoms, which substantially affect quality of life, has proven challenging (4-7). Although post-mortem studies, imaging and human genetic studies have contributed to theories about pathophysiological mechanisms in schizophrenia, the underlying molecular processes have not been fully elucidated.
Genetic studies provide a valuable resource to investigate the mechanisms that are likely at play in schizophrenia. Schizophrenia is highly heritable (h 2 ~ 80%) and polygenic, with genome-wide association studies (GWAS) identifying 108 independent associated risk loci (8, 9) . Pathway and gene set enrichment analysis methods are widely used to provide biological context to the results of such genetic association studies by testing whether biologically relevant pathways or sets of genes are enriched for genetic variants associated with a phenotype (10) (11) (12) . Pathway analyses using data derived from the latest schizophrenia GWAS (8) have shown enrichment of schizophrenia-associated variants in neuronal, immune and histone pathways, and the involvement of calcium signaling processes (13, 14) , but these studies have not used the most complete and recent GWAS data (8) . Additionally, several valuable and widely used pathway analysis tools have not yet been applied to these data, despite their input from comprehensively annotated databases and success in elucidating biology of other common diseases (15) (16) (17) .
Aiming to comprehensively investigate the possible biological processes underlying schizophrenia, we set out to apply gene set and pathway enrichment analysis methods to the latest GWAS in schizophrenia (N = 43,241 cases and 45,604 controls) ( Figure 1 ) (8) . Our results elucidate the involvement of neuronal differentiation and synaptic plasticity in . CC-BY-NC-ND 4.0 International license not peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was . http://dx.doi.org/10.1101/117481 doi: bioRxiv preprint first posted online Mar. 17, 2017; schizophrenia, and signal an accumulation of variants in post-synaptic signaling cascades.
They moreover enable a more nuanced understanding of the several actionable classes of neurotransmitters implicated in the disease.
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Methods and materials

Input data and analysis overview
We used summary-level results from the largest and most recent GWAS in schizophrenia, made publically available by the Psychiatric Genomics Consortium (8) (www.med.unc.edu/pgc/results-and-downloads; downloaded on 10 May, 2017), containing results from approximately 9.4 million single nucleotide polymorphisms (SNPs) tested. As detailed below (also see Figure 1 ), using Multi-marker Analysis of GenoMic Annotation (MAGMA) (18) we successively (A) mapped SNPs to genes, (B) calculated gene p-values based on enrichment from GWAS data, (C) performed a primary gene set enrichment analysis using gene ontology (GO) terms, and (D) followed these findings up by a validation analysis on detailed molecular pathways derived from KEGG. Finally, we validated the results of the analysis on KEGG pathways using Meta-Analysis Gene-set Enrichment of variaNT Associations (MAGENTA) (19) .
Mapping SNPs to genes and assigning p-values to genes
Autosomal SNPs present in the European subset of the 1000 Genomes Phase 3 dataset were extracted from the GWAS summary-level results (20). Using MAGMA v1.06, we mapped SNPs to corresponding genes, extending gene footprints by an additional 20 kilobase (kb) upand downstream, as a large proportion of regulatory elements involved in gene expression regulation is likely to be captured by including this region (21) . We then applied a gene analysis to obtain a p-value for each gene to which at least one SNP was mapped. The pvalue of a gene was based on the mean 2 statistic of SNPs contained in that gene, obtained using a known approximation of the sampling distribution. The European subset of 1000
Genomes Phase 3 was used as a reference dataset to estimate linkage disequilibrium (LD)
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Gene Ontology (GO) term enrichment analysis
We applied a competitive gene set analysis on 4,436 biological processes included in the GO database, using the genes and assigned p-values from the previous step. Gene sets were downloaded from the Molecular Signatures Database (MSigDB, release 6.0, April 2017), a regularly updated database of pathways and gene sets (22, 23) . The significance threshold was adjusted for multiple GO terms tested using a permutation procedure (10, .
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Results
By performing a primary enrichment analysis in MAGMA (in 4,436 biological processes described in the GO database) we identified two terms that were enriched for schizophreniaassociated SNPs ( were highly enriched ( Figure 3, Supplementary Figure 3) .
. CC-BY-NC-ND 4.0 International license not peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was . http://dx.doi.org/10.1101/117481 doi: bioRxiv preprint first posted online Mar. 17, 2017; When conditioning the competitive gene set analysis of each KEGG pathway in on the other pathways tested, thereby using overlapping genes in other pathways as a covariate in the analysis and adjusting for the effect of shared genes between pathways, the enrichment pvalue of all pathways dropped (Supplementary Figure 4) . None of the pathways remained significant at the established significance threshold (p = 0.009), indicating a contribution of shared genes to the enrichment signal.
Using MAGENTA with the same data and gene sets, we also found significant enrichment of the dopaminergic synapse (multiple test-corrected FDR = 5.0 × 10 -4 ), long-term potentiation (corrected FDR = 2.8 × 10 -3 ) and cholinergic synapse (corrected FDR = 4.8 × 10 -3 ) pathways ( Figure 2C ). We thus confirm our above-mentioned findings.
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Discussion
By implementing complementary gene set enrichment analysis tools (MAGMA and MAGENTA) and annotations from biological databases (GO and KEGG) into a comprehensive analysis, we aimed to elucidate biological processes underlying schizophrenia. Thus, we first detected enrichment of schizophrenia-associated SNPs in synaptic plasticity and neuronal differentiation processes, which is in line with biological hypotheses that previous studies have made (8, 13, 14, 26, 27) . We followed this up in a targeted analysis on gene sets representing synaptic signaling in all major neurotransmitter systems, and demonstrated enrichment of schizophrenia SNPs in the dopaminergic and cholinergic systems and in long-term potentiation through the glutamatergic system. Dysfunctional synaptic transmission impacts synaptic plasticity and brain development, mediated through long-term potentiation (LTP) and long-term depression (LTD) (28) . Although all five major neurotransmitter systems (dopamine, gammaaminobutyric acid, glutamate, serotonin, and acetylcholine) have been implicated in schizophrenia, the extent to which each of them is involved had remained elusive (6, 29). We here studied SNP enrichment in these processes, using gene sets of major neurotransmitter systems from the KEGG database, in which we also visualized this enrichment. Our results strongly support the involvement of the dopaminergic system, which has been extensively examined in schizophrenia. Previous studies have reported increased dopamine synthesis and release, and increased dopamine receptor expression in schizophrenia (6, 30) . DRD2 genetic variants are also implicated in schizophrenia and several of its intermediate phenotypes (31, 32) . We here confirm an accumulation of DRD2 genetic variants in schizophrenia. Moreover, we extend this evidence for involvement of the dopaminergic system by highlighting enrichment of variants in signaling cascades downstream of this receptor. Cholinergic transmission may also be relevant to symptomatology of schizophrenia, especially in light of .
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Mediation of LTP is, however, not limited to the glutamatergic system as post-synaptic signaling molecules such as the above mentioned CREB, IP 3 R and PKB mediate synaptic plasticity in other neurotransmitter systems (e.g. the dopaminergic system). Multiple lines of evidence link LTP to cognitive deficits in schizophrenia (36) .
Our detailed analysis of downstream signaling cascades in all major neurotransmitter system gene sets revealed several of these cascades to be highly enriched for schizophrenia- we report enrichment of schizophrenia-associated SNPs. Gene deletions in PLC are associated with schizophrenia and altered expression of Plc and schizophrenia-like behavior have been reported in Plc knock-out mice (38) (39) (40) . Second, signaling through the cellular transcription factor CREB modulates synaptic plasticity. A recent study focusing on the cyclic adenosine monophosphate (cAMP)/PKA/CREB pathway shows a significant association of a SNP in this system with schizophrenia (27) . Additionally, ERK is part of the CREB signaling cascade and was also found to be enriched in our analyses. Impairment of signaling through ERK is hypothesized as a disease mechanism in schizophrenia (41, 42) . PP2A is one of the mediators of sensorimotor gating, an intermediate phenotype for schizophrenia (46) . Several limitations should be considered when interpreting our results. First, no significant SNP enrichment was found in other systems hypothesized to be dysregulated in schizophrenia, such as glutamatergic and GABAergic neurotransmission (6, 47, 48) . As our analyses are dependent on the power of GWAS, we cannot rule out the possibility that increased sample sizes in future studies may flag such systems. Second, we can only test for enrichment in gene sets and pathways that are annotated based on the knowledge currently available. Third, only protein-coding regions of the genome and up-and downstream regions in close proximity to genes were considered in our analyses. Recently, it has become clear that non-coding stretches of the genome account for a major part of disease heritability and transcription regulation (35, 49) . As the current analyses do not allow us to probe non-coding regions, we cannot take into account the effects that such genomic areas may have on neurotransmitter systems. Despite these limitations and slight technical differences between MAGMA and MAGENTA (18, 19) , such as in computation of gene p-values and calculation of gene set enrichment, we found the same pathways to be significantly enriched in results generated from each approach, suggesting our finding is robust to analytic approach. Future integration of expression quantitative trait locus (eQTL) data and genomic interactions in 17, 2017; pathway analysis tools has the potential to further deepen our understanding of the molecular mechanisms involved in the pathways underlying schizophrenia.
In conclusion, using two complementary enrichment analysis approaches, we highlight downstream signaling cascades as the most likely part of the dopaminergic, cholinergic and glutamatergic (mediating LTP) systems to have a role in schizophrenia.
Conditional analysis correcting mainly for shared genes showed a non-significant enrichment of all neurotransmitter gene sets, supporting the hypothesis that shared signaling mechanisms across the implicated pathways are likely to be a stronger underlying factor in schizophrenia than the independent neurotransmitter systems. Genes involved in these shared signaling mechanisms might be core genes which are more important in schizophrenia pathology, a concept that has been extensively outlined in a recent publication (50) . Our results open avenues for further research aimed at elucidating signaling pathways in schizophrenia, e.g. through tissue-specific manipulation of pathways in animal or cell models. Finally, our findings may aid the discovery of novel drug targets to hopefully reduce the burden imposed on quality of life in patients suffering from this disabling disorder.
Acknowledgments
None.
Financial disclosures
No funding was provided to carry out the current project. The copyright holder for this preprint (which was . http://dx.doi.org/10.1101/117481 doi: bioRxiv preprint first posted online Mar. 17, 2017; protein kinase B; Erk, Extracelluar signal-regulated kinase; CREB, cAMP response element binding protein; CBP, CREB-binding protein; PP1, protein-phosphatase 1; PLC, phospholipase C; IP 3 R, inositol trisphosphate receptor; PP2B, protein-phosphatase 2B.
CC-BY-NC-ND
